As cell and gene therapies (CGTs) continue to advance, they have unique developmental features that may require innovation in ...
This population-based study found that updated infant feeding guidelines in Australia recommending earlier introduction of ...
Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...
Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ...
Today, MLCommons ® announced new results for the MLPerf ® Training v6.0 benchmark suite. The two new benchmarks added in this ...
The risk of cognitive outsourcing is real. But there is reason for optimism, if students are taught good AI habits early and ...
Scaling effective solutions often stalls in state government because funding systems are not designed to reward proof of ...
Morning Overview on MSN
Daraxonrasib nearly doubled survival in metastatic pancreatic cancer, cutting the risk of death by 60% in a 500-patient trial
Patients with previously treated metastatic pancreatic cancer lived roughly twice as long on a daily oral drug called ...
Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with ...
AbCellera has an AI-driven antibody discovery platform, $650M liquidity, and an upcoming Phase 2 catalyst. Click here to read ...
A phase 2 trial shows combining intravesical recombinant BCG with chemoimmunotherapy in MIBC yields a higher than expected pathologic complete response rate. Intravesical recombinant bacillus Calmette ...
High mortality in elderly patients followed over a decade might complicate the lessons learned compared with SAVR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results